Morse Asset Management Inc Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Morse Asset Management Inc raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,764 shares of the biopharmaceutical company’s stock after buying an additional 180 shares during the quarter. Regeneron Pharmaceuticals comprises 1.2% of Morse Asset Management Inc’s holdings, making the stock its 26th largest position. Morse Asset Management Inc’s holdings in Regeneron Pharmaceuticals were worth $5,007,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Global Assets Advisory LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $339,594,000. Capital International Investors increased its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares during the period. First Trust Advisors LP raised its stake in shares of Regeneron Pharmaceuticals by 115.2% in the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after purchasing an additional 195,902 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after purchasing an additional 184,561 shares during the period. Finally, TD Asset Management Inc boosted its position in Regeneron Pharmaceuticals by 162.9% in the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after buying an additional 166,998 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.4 %

Shares of Regeneron Pharmaceuticals stock opened at $1,145.03 on Monday. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $769.19 and a twelve month high of $1,211.20. The firm has a market capitalization of $126.17 billion, a PE ratio of 33.83, a P/E/G ratio of 3.93 and a beta of 0.12. The firm’s 50-day moving average price is $1,131.75 and its 200 day moving average price is $1,032.63.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the business posted $8.79 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the transaction, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The disclosure for this sale can be found here. Insiders sold 9,270 shares of company stock valued at $10,695,833 over the last 90 days. 7.48% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

REGN has been the subject of a number of recent research reports. Wells Fargo & Company raised their price target on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Argus increased their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. JPMorgan Chase & Co. lifted their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,111.30.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.